Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema

European Respiratory Journal

Volumn 21, Issue 3, 2003, Pages 444-449

  Ferrarotti, I ^a   Zorzetto, M ^a   Beccaria, M ^a   Gile L S ^b   Porta, R ^b   Ambrosino, N ^b   Pignatti, P F ^c   Cerveri, I ^a   Pozzi, E ^a   Luisetti, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Association study; Candidate gene; Complex traits; Gene polymorphisms; Polymerase chain reaction

Indexed keywords

CARBON MONOXIDE; DNA; LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AIRWAY OBSTRUCTION; ALLELE; ARTICLE; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EXON; FORCED EXPIRATORY VOLUME; GENE LOCATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INTRON; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; VITAL CAPACITY;

EID: 0037345725     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00051303     Document Type: Article

References (46)

1. Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1380-1391.
2. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54: 245-252.
3. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001; 2: 20-26.
4. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
5. Huang S-L, Su C-H, Chang S-C. Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1436-1439.
6. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor α gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 420-422.
7. Patuzzo C, Gilé LS, Zorzetto M, et al. Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest 2000; 117: 1353-1358.
8. Higham MA, Pride NB, Alikhan A, Morrell NW. Tumour necrosis factor-α gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000; 15: 281-284.
9. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Paré PD. Susceptibility genes for rapid decline of lung function in the Lung Health Study. Am J Respir Crit Care Med 2001; 163: 469-473.
10. Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000; 16: 768-780.
11. Iannuzzi MC, Maliarik M, Rybicki B. Genetic polymorphisms in lung disease: bandwagon or breakthrough? Respir Res 2002; 3: 15.
12. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635-642.
13. Widzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax 2000; 55: 631-632.
14. Snider GL. Changes in COPD occurrence. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis 1989; 140: S3-S8.
15. Hoidal JR. Genetics of COPD: present and future. Eur Respir J 2001; 18: 741-743.
16. Ishii T, Matsuse T, Teramoto S, et al. Neither IL-1β, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD. Respir Med 2000; 94: 847-851.
17. Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor necrosis factor-α gene promoter region may predispose to a poor prognosis in COPD. Chest 2000; 118: 971-975.
18. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-α gene correlates with a variant amino acid in position 26 and a reduced level of TNF-α production. J Exp Med 1991; 173: 209-219.
19. Chan FK-M, Siegel RM, Lenardo MJ. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000; 13: 419-422.
20. Sedgwick JD, Riminton DS, Cyster JG, Körner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today, 2000; 21: 110-113.
21. Silverman EK, Palmer LJ. Case-control associations studies for the genetics of complex respiratory disorders. Am J Respir Cell Mol Biol 2000; 22: 645-648.
22. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
23. Morrison NJ, Abboud RT, Ramadan F, et al. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema. Am Rev Respir Dis 1989; 139: 1179-1187.
24. Baldi S, Miniati M, Bellina CR, et al. Relationship between extent of pulmonary emphysema by high-resolution computer tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 585-589.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization for lung volumes tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
26. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med 1995; 152: 1107-1136.
27. Pitts SA, Olomolaiye OO, Elson CJ, Westacott CI, Bidwell JL. An MspA1 I polymorphism in exon 1 of the human TNF receptor type I (p55) gene. Eur J Immunogenet 1998; 25: 269-270.
28. Al-Ansari AS, Ollier WER, Villareal J, Ordi J, Teh L-S, Hajeer AH. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000; 55: 97-99.
29. Pauwels RA, Buist SA, Calverly PM, Jenkins CR, Hurd SS and the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
30. Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M. Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 2001; 98: 10781-10786.
31. Sorlie PD, Kannel WB, O'Connor GT. Mortality associated with respiratory function and symptoms: the Framingham Study. Am Rev Respir Dis 1989; 140: 379-384.
32. 1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J 2001; 17: 1097-1104.
33. Gelb AF, Schein M, Kuei J, et al. Limited contribution of emphysema in advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147: 1157-1611.
34. Gelb AF, Zamel N, Hogg JC, Müller NL, Schein M. Pseudophysiologic emphysema resulting from severe small-airways disease. Am J Respir Crit Care Med 1998; 158: 815-819.
35. Gelb AF, Hogg JC, Müller NL, et al. Contribution of emphysema and small airways in COPD. Chest 1996; 109: 353-359.
36. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
37. Keatings VM, Collins PD, Scott PD, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 152: 1646-1652.
38. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150: 1453-1455.
39. Schols AMWJ, Creutzberg EC, Buurman WA, Campfield LA, Saris WHM, Wouters EFM. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1220-1226.
40. Hohjoh H, Terada N, Kawashima M, Honda Y, Tokunaga K. Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with narcolepsy. Tissue Antigens 2000; 56: 446-448.
41. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K. Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 1999; 53: 527-533.
42. Barton A, John S, Ollier WER, Silman A, Worthington J. Association between rheumatoid arthritis and polymorphism of the tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum 2001; 44: 61-65.
43. Pantelidis P, Fanning GC, Wells AU, Welsh KI, du Bois RM. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163: 1432-1436.
44. Pantelidis A, Lympany PA, Foley PJ, Fanning GC, Welsh KI, du Bois RM. Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2. Tissue Antigens 1999; 54: 585-591.
45. Joost O, Wilk JB, Cupples LA, et al. Genetic loci influencing lung function. A genomwide scan in the Framingham Study. Am J Respir Crit Care Med 2002; 165: 795-799.
46. Silverman EK, Palmer LJ, Mosley JD, et al. Genomwide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002; 70: 1229-1239.